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SUMMARY. The main objectives of this study were to define
the occurrence and levels of hepatitis B virus (HBV) DNA in
asymptomatic HBV carriers, cirrhosis patients and hepato-
cellular carcinoma (HCC) cases from The Gambia, and to
evaluate the risk for cirrhosis or HCC associated with HBV
viremia. We used sensitive real-time quantitative PCR assays
to measure HBV DNA in samples from a case–control study
consisting of 60 asymptomatic HBV carriers, 53 cirrhotic
patients and 129 HCC cases. Logistic regression was used to
estimate the risks of cirrhosis and HCC associated with HBV-
DNA levels and HBV e antigenemia (HBeAg) detection (a
surrogate marker for viral replication). Detectable HBV
viremia and HBeAg positivity were both significantly asso-
ciated with cirrhosis (increasing risk by fourfold and 11-fold
respectively) and with HCC (increasing risk by sixfold and
threefold respectively). HBV-DNA levels were significantly
higher in both HCC cases and cirrhotic patients compared to
asymptomatic carriers (P < 0.01 for both). High-level HBV
DNA (>10 000 copies/mL) was strongly associated with
both HCC and cirrhosis (17- and 39-fold increased risk).
Lower level HBV viremia (200–10 000 copies/mL) conferred
a significant risk of HCC, although the association with cir-
rhosis was not significant. In conclusion, we find that high
HBV-DNA levels are strongly associated with the serious
sequelae of HBV infection, independent of HBeAg status.
While risk for cirrhosis and for HCC notably increases at
HBV-DNA levels ‡10 000 copies/mL, low-level viremia was
also associated with significant risk for HCC.
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INTRODUCTION
Hepatitis B virus (HBV) is the leading cause of hepatocellular
carcinoma (HCC) worldwide, particularly in Asia and sub-
Saharan Africa [1]. In these endemic regions, HBV infection
is generally acquired at birth or in early childhood with up to
10–20% of the adult population persistently expressing HBV
surface antigen (HBsAg, a serologic marker of chronic
infection) [2]. Persons with HBsAg expression are at very
high risk of developing the chronic sequelae of HBV infection
including liver cirrhosis and HCC. However, despite the very
high attributable fraction and relative risk related to HBsAg
positivity, only a minority of chronically infected persons will
develop cirrhosis or HCC. The role of environmental or
behavioural factors (e.g., aflatoxin exposure, alcohol use)
and of host genetic factors have been documented to modify
individual risk for HCC [3–5]. In addition, growing evidence
indicates that differences in HBV outcomes may be closely
associated with viral characteristics, including replication
status and genetic variation of HBV [3,6,7]. Recent studies
conducted in large Asian cohorts indicate that HBV-DNA
levels strongly predicted development of HBV-related cir-
rhosis and HCC [8–10]. In contrast to Asia, there are only
limited data on HBV-DNA detection and quantification
associated with liver disease outcomes among persons from
sub-Saharan Africa.
Hepatitis B virus infection is endemic in The Gambia in
West Africa with a 15–20% prevalence among adults
[11,12]. HCC is the most common cause of cancer and one of
the leading causes of death among Gambians [13]; HBV
Abbreviations: ALT, alanine aminotransferase; AST, aspartate
aminotransferase; GLCS, Gambia Liver Cancer Study; GM, geometric
mean; HBeAg, HBV e antigenemia; HBsAg, HBV surface antigen;
HBV, hepatitis B virus; HCC, hepatocellular carcinoma.
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accounts for around two-thirds of HCC cases [11]. Using
hybrizidation assays, we previously reported that high-titre
serum HBV DNA in adult HBV chronic carriers was corre-
lated with duration of HBV carriage and HBeAg positivity
[14]. However, HBV hybridization assays have limited sen-
sitivity and in response, we recently validated a sensitive
quantitative real-time polymerase chain reaction assay for
measuring serum HBV DNA among Gambian HBV carriers
[15]. In the current study, we apply this assay to measure
HBV-DNA levels in a well-characterized Gambian study
population that includes asymptomatic HBV carriers and
persons with HBV-related cirrhosis or HCC. We hypothesized
that a dose–response association of HBV-DNA level with
advanced liver disease would be observed. Thus, our primary
objectives were to define the occurrence and levels of HBV
viremia and examine their associations with cirrhosis and
HCC in an African population.
MATERIALS AND METHODS
Study participants
Our study population included all HBsAg-positive persons
that had been prospectively recruited into the Gambia Liver
Cancer Study (GLCS), as described previously [11]. Briefly,
participants were recruited from September 1997 through
January 2001 through liver disease referral clinics at three
tertiary hospital sites (Royal Victoria Hospital, Banjul;
Medical Research Council Hospital, Fajara; and Bansang
Hospital, Bansang). Incident cases of cirrhosis or of HCC
were identified from among patients with suspected liver
disease referred by local physicians or identified through
active surveillance of the wards and clinics by GLCS field
staff. All participants were administered a standardized
questionnaire and underwent a clinical examination and
venipuncture; persons with liver disease had a standardized
ultrasound examination performed. HCC was diagnosed
either by pathology or by a combination of ultrasonographic
evidence of space-occupying lesions and a serum a-fetopro-
tein (AFP) level of ‡100 ng/mL. Among individuals without
pathologic or ultrasonographic evidence of HCC, cirrhosis
was diagnosed using an ultrasound scoring system previ-
ously validated to liver histology among HBV-infected per-
sons [10,16,17]. The quantitative cirrhosis score is derived
from the ultrasonographic evaluation of the liver surface,
liver parenchyma, caliber of intrahepatic blood vessels and
spleen size; scores of ‡7 were used to define cirrhosis [18].
Asymptomatic HBV carriers were identified from among
control participants without clinical evidence of liver disease
recruited from the outpatient general medical clinics of the
same hospital sites. Antiviral treatment active against HBV
was not available to study participants. Local and interna-
tional scientific and ethical review committees approved the
study protocol, and informed consent was obtained from
each participant.
Laboratory testing
Following processing within 24 h, blood specimens were
stored at either )20 or )70 C depending on the planned
testing. AFP was detected and quantified by standard
radiometric assay methods (DiaSorin SA, Sallugia, Italy).
Aspartate aminotransferase (AST), alanine aminotransferase
(ALT) and total bilirubin levels were determined on clinical
samples using Roche COBAS MIRA Chemistry Analyzer.
HBsAg was determined by reverse passive haemagglutina-
tion assay (Murex Diagnostics Limited, Dartford, UK) with
radioimmunoassay testing of negative samples (Sorin
Biomedica Diagnostics, Vercelli, Italy). Participants positive
for HBsAg were tested for HBV e antigenemia (HBeAg) as a
surrogate marker of active replication using a radioimmu-
noassay kit (DiaSorin). HBV-DNA detection and quantifica-
tion were performed as described previously [15]. Briefly,
quantitative real-time PCR was carried out using commer-
cial SYBR-Green reaction mix (Qiagen, Hilden, Germany)
and primers specific to the S gene. The primer sequences
were 5¢ GTG TCT GCG GCG TTT TAT CA (sense) and 5¢ GAC
AAA CGG GCA ACA TAC CTT (antisense) designed to
amplify a 98 base pair product from positions 379 to 476 of
the HBV genome. Thermal cycling was performed in an ABI
5700 sequence detection system (PE Applied Biosystems,
Warrington, UK). HBV-DNA concentration was calculated
from a four point standard curve [1.5 · 108, 1.5 · 106,
1.5 · 104 and 1.5 · 102 copies/mL]. Calibration of this
standard was confirmed by comparison with an interna-
tional HBV-DNA standard (97/746; NIBSC, Potters Bar, UK).
The detection limit of the RT-PCR assay was 2.6 · 102 DNA
copies per mL [15], although the qualitative limit of detec-
tion for the assay was established as 2.0 · 102 DNA copies
per mL. Samples testing above the standard curve were
re-assayed at a dilution of 1:100. The assay was 100%
specific when tested against 10 HBV negative sera and
intra- and inter-assay comparisons demonstrated acceptable
reproducibility [15].
Statistical analysis
We calculated descriptive statistics for demographic and
clinical variables by study group. Geometric mean (GM) and
median HBV-DNA levels were determined based on observed
value for participants with quantifiable HBV DNA (‡260
copies/mL) and an estimate of 200 copies/mL for partici-
pants with non-quantifiable but qualitatively detectable HBV
DNA (200–259 copies/mL). We used chi-square, Fishers
exact, unpaired t and unbalanced analysis of variance tests
to evaluate differences among and between the three study
groups. We used unadjusted and adjusted logistic regression
models to evaluate the impact of HBeAg positivity, HBV-
DNA detection status and HBV-DNA level on risk of cirrhosis
or of HCC compared with control individuals. Based on prior
analysis [11], we included age, gender, recruitment site and
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date, education and household floor type in adjusted models.
Education and household floor type were included in each
analysis as markers of socioeconomic status. Participants
tobacco, alcohol consumption and the presence of antibodies
against hepatitis C virus did not qualitatively change any
effect estimates, and were thus excluded from the final
models. Three individuals with incomplete ascertainment of
educational status were excluded from the analyses of risk
for cirrhosis and HCC. All analyses were conducted using
SAS 9.1 (SAS Institute, Cary, NC, USA).
RESULTS
Characteristics of study participants
Demographic and laboratory marker characteristics of the
60 asymptomatic HBV carriers, 53 HBV-related cirrhotic
patients and 129 HBV-related HCC cases are presented in
Table 1. All three groups were majority male with gender
ratios ranging from 3.3 to 5.3 males per female. The
majority of participants were under 45 years of age with
minimal differences in this proportion by study group
(asymptomatic carriers, 61%; cirrhosis cases, 63%; HCC
cases, 59%). Study participants often lived in homes with
earthen floors but most had received at least some formal
schooling. Recruitment site and socioeconomic status vari-
ables did not differ significantly between the three study
groups. Cigarette smoking was relatively common in this
population although alcohol consumption was not (data not
shown); the proportions of smokers and drinkers did
not vary significantly between the study groups. Elevated
AST and bilirubin levels were seen more frequently in the
cirrhosis and HCC case groups compared to asymptomatic
carrier group (both P < 0.01), while the occurrence of
elevated ALT was infrequent and similar across the three
groups.
HBV markers by study group and demographic variables
Circulating HBeAg was detected in only 3% of asymptomatic
carriers compared to 28% and 18% of cirrhosis and HCC
cases respectively (Table 2). When examining the distribu-
tion of HBeAg postivity by age group (Fig. 1a), the propor-
tion of cirrhosis and HCC cases who were HBeAg positive
was higher than among asymptomatic carriers regardless of
age; notably, we did not detect HBeAg among any asymp-
tomatic HBV carriers over 44 years of age. Cirrhosis cases
tended to have a higher proportion with HBeAg expression
than HCC cases across most age strata.
Cirrhosis and HCC cases more commonly had detectable
HBV viremia and higher viral load levels compared to
asymptomatic HBV carriers (Table 2). Over 80% of cirrhosis
Table 1 Characteristics of 242 HBV e antigenemia (HBeAg)-
positive participants by study group
Variable
HBV Carriers
(n = 60)
N (%)
Cirrhosis cases
(n = 53)
N (%)
HCC cases
(n = 129)
N (%)
Demographic
Male gender 49 (82) 41 (77) 108 (84)
Mean age ± SD
(years)
41 ± 16 39 ± 12 42 ± 13
Site
RVH 17 (28) 28 (53) 54 (42)
MRC 21 (3) 13 (25) 40 (31)
BSG 22 (37) 12 (23) 35 (27)
Education
Ever school 56 (93) 44 (83) 103 (80)
None 4 (7) 9 (17) 23 (18)
Unknown 0 (0) 0 (0) 3 (2)
Earth floor
Yes 34 (57) 21 (40) 50 (39)
No 26 (43) 32 (60) 79 (61)
Laboratory
AST (IU/L)
AST ‡ 45 8 (13) 30 (57) 95 (74)
Missing 1 (2) 2 (4) 11 (9)
ALT (IU/L)
ALT ‡ 45 2 (3) 2 (4) 7 (5)
Missing 2 (3) 2 (4) 11 (9)
Bilirubin (mg/dL)
Bilirubin ‡ 20 16 (27) 37 (70) 67 (52)
Missing 3 (5) 3 (6) 18 (14)
Table 2 Hepatitis B virus (HBV) markers
by study group
Variable
HBV Carriers
(n = 60)
N (%)
Cirrhosis Cases
(n = 53)
N (%)
HCC Cases
(n = 129)
N (%)
HBeAg+ 2 (3.3) 15 (28) 23 (18)
HBV DNA+ 24 (41.7) 43 (81.1) 114 (88.4)
HBV-DNA levels,
Geometric Mean
(Log10 Mean) in
copies/mL
4143 (3.62) 2 887 109 (6.46) 634 794 (5.80)
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and HCC cases had HBV-DNA detected compared to only
42% of asymptomatic carriers (P < 0.01 for both compari-
sons). Among those participants with detectable HBV DNA,
the GM of HBV-DNA levels among cirrhosis cases (6.46
log10 copies/mL) and HCC cases (5.80 log10 copies/mL)
were more than 2 to 3 log10 higher, respectively, than
observed among asymptomatic carriers (3.62 log10 copies/
mL; P < 0.01 for both comparisons). Similar relationships by
study group were also observed when median HBV-DNA
levels were examined with 1247 copies/mL, 6 398 892
copies/mL and 323 443 copies/mL for controls, cirrhosis
and HCC cases, respectively. The findings of a lower pro-
portion of viremia and lower viral load among asymptomatic
carriers compared to subjects with advanced liver disease
was consistently observed across all age groups (Fig. 1b, c).
Hepatocellular carcinoma cases 55 years of age and older
tended to have a lower proportion of HBV-DNA detection
(75%) compared to younger HCC cases (90.8% HBV DNA
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positive among those <55 years, P = 0.058). In contrast, all
cirrhosis cases 55 years of age and older had detectable HBV
DNA compared to 79.2% among younger cirrhosis cases
P = 0.57). Overall, HBV-DNA levels among cirrhosis cases
were higher (0.75 log10) than that of HCC cases
(P = 0.05). Further, this relationship of higher HBV-DNA
levels among cirrhosis cases compared to HCC cases was
observed within all age strata except for the youngest
grouping of persons under 35 years of age (Fig. 1bc).
The distribution of HBV-DNA detection and viral loads
within study groups, stratified by HBeAg status, are pre-
sented by age groupings and by gender in Table S1. HBeAg
was perfectly predictive of HBV viremia as all HBeAg positive
participants were also HBV-DNA positive. However, despite
the commonly referenced use of HBeAg as a marker of HBV
viral replication, 40% (23/58) of asymptomatic carriers,
74% (28/38) of cirrhosis cases and 86% (91/106) of HCC
cases that were HBeAg negative had detectable HBV DNA
(P = 0.01). GM viral loads were significantly higher among
HBeAg positive compared with HBeAg negative cirrhosis
and HCC cases (P < 0.01 for both). The two HBeAg positive
asymptomatic carriers displayed much higher HBV-DNA
levels compared with 58 HBeAg negative carriers; however,
this comparison was limited by small numbers and was of
borderline statistical significance (P = 0.05). Among HBeAg
negative participants, higher HBV-DNA levels among
cirrhosis cases compared with HCC cases were observed
across all ages represented in the study.
Overall, male and female participants had similar
proportions with detectable HBV DNA (76% vs 70%,
respectively; P = 0.42) and GM viral loads (478 319 vs
356 034, respectively; P = 0.77). Gender-specific data on
HBV-DNA detection and viremia stratified by study group
and HBeAg status are presented in Table S1. Among HBeAg
negative participants, males displayed higher HBV-DNA
levels compared with females within each study group. In
contrast, among HBeAg positive participants, males had
lower HBV viral loads than females within each study group.
However, these gender comparisons of HBV-DNA levels were
limited by many strata having relatively small numbers,
particularly for HBeAg positive women.
HBeAg and HBV-DNA detection and risk of cirrhosis and
HCC
After adjustment for age, gender, recruitment site, date and
socioeconomic status, HBeAg positivity was associated
with a significant 11.2-fold risk for cirrhosis and a 6.7-fold
increased risk of HCC (Table 3). Adjusting for these same
variables in a separate model, HBV viremia was significantly
associated with both cirrhosis and HCC, increasing the risk
by 5.7- and 12.1-fold respectively.
In addition, we sought to estimate the independent risk for
cirrhosis or HCC associated with HBeAg or HBV DNA, while
accounting for detection of the other marker (Table 3). Even
after adjustment for HBeAg status and other potential
confounders, HBV viremia was significantly associated
with both cirrhosis and HCC, increasing the risk by 4.1- and
10.5-fold respectively. While accounting for HBV-DNA
detection, HBeAg positivity was associated with a significant
6.2-fold risk for cirrhosis and a 3.2-fold, but non-significant,
increased risk of HCC.
HBV-DNA levels and risk of HCC and cirrhosis
Adjusting for age, gender, recruitment site and date and
socioeconomic status (Table 4), low-level HBV viremia
(200–10 000 copies/mL) conferred a significant risk of HCC,
but was not associated with cirrhosis compared to asymp-
tomatic carriers. In contrast, high-level HBV viremia
(>10 000 copies/mL) was strongly associated with both
HCC and cirrhosis, conferring significant 17.3- and 38.8-fold
increased risks of cirrhosis and HCC respectively.
DISCUSSION
In the current study, we present evidence that detection and
quantification of HBV DNA among chronically infected
Table 3 HBV e antigenemia (HBeAg)
and HBV-DNA detection and risk of
cirrhosis and HCC
Controls
(n = 60)
Cirrhosis patients
(n = 53) HCC cases (n = 126)
Referent OR *OR 95% CI OR *OR 95% CI
HBeAg+ 1.0 11.4 11.2 2.0, 61.5 6.1 6.7 1.5, 31.3
HBV DNA+ 1.0 6.0 5.7 2.0, 15.9 11.2 12.1 5.3, 27.9
Combined model
HBeAg+ 1.0 6.2 6.2 1.1, 34.1 2.8 3.2 0.7, 15.3
HBV DNA+ 1.0 4.3 4.1 1.4, 11.8 9.8 10.5 4.5, 24.5
OR, unadjusted odds ratio; *OR, odds ratio adjusted for age, gender, recruitment
site and date, education and household floor type; HCC, hepatocellular carcinoma.
95% confidence interval presented is for the adjusted OR
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persons provides valuable information for estimating risk for
both cirrhosis and HCC. Our findings extend the utility of
HBV-DNA measurements for predicting cirrhosis or HCC risk
to include HBV-infected persons from sub-Saharan Africa.
Further, despite the well-recognized difference in circulating
HBV genotypes and the prevalence of viral mutations
between Asian and African populations, we provide addi-
tional support that the threshold of 10 000 copies/mL of
HBV DNA is important in the decision of antiviral treatment
candidacy. However, our data raise further questions
regarding the HCC risk associated with detectable HBV DNA
at levels <10 000 copies/mL, and as such, appropriate
management of persons with lower level HBV replication.
The recognition that relatively few chronic HBsAg-posi-
tive carriers manifest complications of HBV, the appreciation
that productive viral replication commonly occurs in the
absence of HBeAg, and the need for determining eligibility
and for monitoring anti-HBV therapy all highlight the need
for improved HBV biomarkers. Our current study applied a
previously validated in-house RT-PCR assay to measure
HBV-DNA levels among well-characterized participants in
the Gambia Liver Cancer Study [11,15]. Importantly, all risk
estimates associated with HBV-DNA measurements were in
comparison with chronically infected, but asymptomatic
persons expressing HBsAg of similar age to the cases. Our
application of sensitive real-time PCR methods could detect
low levels of HBV viremia. Simple categorization of HBV
viremia as present was associated with a sixfold and a
12-fold increased risk for cirrhosis or HCC respectively.
Further, we identified a dose–response increase in HCC risk
with increasing levels of HBV DNA, up to a 39-fold risk
associated with levels >10 000 copies/mL.
Large-scale cohorts with lengthy follow-up among
Taiwanese HBV carriers have provided prospective data
documenting an increased risk for cirrhosis and for HCC
with increasing levels of HBV DNA [7,8,10]. Because of the
differences in study design, risk estimates for cirrhosis and
HCC with HBV viremia reported from our case–control study
with HBV DNA measured at diagnosis, may not be directly
comparable with estimates from the Asian cohort studies
with HBV DNA measured on stored samples obtained
10–15 years prior to diagnosis [10]. If HBV-DNA levels
decline over time to a greater degree among asymptomatic
carriers compared with persons who develop advanced
disease, risk estimates based on levels measured at diagnosis
may overestimate risk. Conversely, if HBV DNA declines are
accelerated among diseased compared to non-diseased, our
risk estimates would be underestimated. Finally, if declines
in HBV-DNA levels are comparable between persons who
develop disease and similarly aged carrier controls, the risk
estimates should also be comparable.
Only limited data are available to evaluate persistence of
HBV-DNA levels. Chen and colleagues evaluated HBV-DNA
levels from the visit just prior to HCC diagnosis on subjects
with baseline HBV-DNA levels >10 000 copies/mL (median
duration of interval follow-up was 10 years) [9]. HCC risk
was most closely predicted by the proximate HBV-DNA
measure; baseline levels of 10 000–99 000 copies/mL were
not associated with significantly increased risk except among
the 21% of persons with HBV-DNA levels increasing to
>100 000 copies/mL. In subsequent detailed analysis of
long-term HBV viral load measures in this cohort, the
authors reported that while HCC cases had higher baseline
viral loads, their HBV-DNA levels decreased more rapidly
during follow-up compared to non-cases [19]; this suggests
that our case–control study risk estimates may in fact be
conservative. Importantly, if the baseline HBV-DNA measure
was greater than 10 000 copies/mL in the Taiwanese
cohort, the probability of maintaining stable levels above this
threshold was high. Their data suggest that persistently
elevated HBV-DNA levels are most predictive of developing
HCC and support our premise that these markers are durable
and useful for estimating risk later in the disease process.
Despite a similar overall prevalence of HBV carriage, there
are marked differences in HBV infection between Asian and
African populations. While perinatal transmission is com-
mon in Asian populations, horizontal transmission among
young children predominates in Africa [2]. Differences in
circulating HBV genotypes, HBeAg persistence, host genetics
and exposure to cofactors such as aflatoxin may also con-
tribute to a differing course of HBV infection between Asians
and Africans. With all these population differences, it is
remarkable that our findings from The Gambia are largely
consistent with the prior Asian studies.
Table 4 Hepatitis B virus (HBV)-DNA
levels and risk of cirrhosis and HCC
HBV DNA (copies/mL)
Controls
(n = 60)
Cirrhosis cases
(n = 53)
HCC cases
(n = 126)
Referent OR *OR 95% CI OR *OR 95% CI
200–10 000 1.0 1.2 1.0 0.3, 3.9 3.1 3.1 1.2, 8.2
>10 000 1.0 18.5 17.3 4.2, 71.2 32.1 38.8 12.1, 124.5
OR, unadjusted odds ratio; *OR, odds ratio adjusted for age, gender, recruitment
site and date, education and household floor type and for HBeAg status; HCC,
hepatocellular carcinoma. 95% confidence interval presented is for the adjusted
OR.
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To our knowledge, only one prior study estimated HCC
risk related to HBV-DNA measurements in an African pop-
ulation. Among 14 HCC cases matched to 22 HBsAg positive
controls identified in a cohort of males in the Senegalese
Army, Tang and colleagues reported a 16-fold increased risk
with HBV-DNA detection [20], comparable to our risk esti-
mate of 12.1 (Table 3).
Consistent findings suggest that risk for HCC associated
with HBV-DNA levels increases in a dose–response fashion,
but it remains unclear at what lower limit HCC risk may be
negligible. Determination of the safe threshold of HBV-DNA
levels where the development of HBV-related complications
is unlikely is of great importance in determining appropriate
screening and antiviral management guidelines.
Prior studies of HBV viremia have largely focused on HCC
as the primary endpoint. Chen and colleagues reported risk
for cirrhosis and HCC outcomes achieving statistical signifi-
cance at ‡10 000 copies/mL [9,10]. In a large prospective
cohort in Haimen City in China, significantly increased risk
for HCC and cirrhosis mortality was not observed until
‡100 000 copies/mL [9]. Our data suggested that while
lower level viremia (200–10 000 DNA copies/mL) was
significantly associated with HCC, risk for cirrhosis did not
increase until ‡10 000 copies/mL. Interestingly, we found
that HBV-DNA levels appeared to be higher among cirrhotic
compared to non-cirrhotic HCC. Although viral factors
largely did not differ between HBV-related non-cirrhotic
compared to cirrhotic HCC in a Taiwanese study, there was a
borderline association of higher viral load in cirrhotic HCC
[21]. Younger HCC patients with lower HBV viral loads are
less likely to have coexistent cirrhosis compared to older HCC
cases with higher viremia [22].
These epidemiologic data can suggest mechanisms that
may be involved in the pathogenesis of HBV-related cirrhosis
and HCC. Replicative HBV infection is the stimulus for
host immune responses leading to the chronic process of
hepatocyte destruction and regeneration with development
of fibrosis and eventually cirrhosis. As such, it may be that a
certain threshold level of HBV replication is required to lead
to development of cirrhosis.
It remains unclear whether HBeAg plays a direct biolog-
ical role or merely represents a long-recognized surrogate
marker for HBV replication [23]. HBeAg postivity is strongly
associated with increased risk for HCC [6,11] while HBeAg
seroconversion is mostly accompanied by resolution of
necroinflammatory liver changes and reduced or undetect-
able HBV-DNA levels [24,25]. In our study, while all HBeAg
positive participants were HBV-DNA positive, less than half
of HBeAg negative asymptomatic carriers had detectable
viremia. However, only 15–25% of those with cirrhosis or
HCC expressed HBeAg at diagnosis. The incremental value of
HBeAg status to predict liver disease risk was assessed
(Table 3); interestingly, risk estimates for both cirrhosis and
for HCC related to HBeAg positivity were reduced by almost
half after accounting for HBV viremia. Assessment of the role
of HBeAg-negative variants in relation to HBV-DNA levels
and disease outcomes will be key to fully understand the
mechanisms involved.
Our study had several challenges. Despite being one of
largest of the few studies of HBV DNA in HCC or cirrhosis
from Africa, some of our analyses were limited by having
small numbers. As discussed above, the cross-sectional
nature of our study evaluates HBV-DNA levels at time of
diagnosis so the disease process itself may impact our
measured levels. While we are unable to equivocally state
what long-term predictive value HBV-DNA levels have in
estimating risk for HBV-related liver disease, the consistency
of our findings to previous studies, especially those with
testing near time of diagnosis, supports our ability to make
strong inferences.
In conclusion, we find that HBV-DNA levels are strongly
associated with the serious sequelae of HBV infection, inde-
pendent of HBeAg status. While risk for cirrhosis and for
HCC notably increases at HBV-DNA levels ‡10 000 copies/
mL, low-level viremia was also associated with significant
risk for HCC. Growing evidence suggests that suppression of
HBV, even if only for a finite time period, may significantly
reduce risk for developing HCC [26]. Further application of
sensitive HBV-DNA assays to appropriate study populations
should improve our ability to target HBV-infected persons at
highest risk for disease progression and most appropriate for
antiviral therapy. In recent years, the successful introduc-
tion and dissemination of antiviral therapy for HIV infection
(commonly including drugs with anti-HBV efficacy) in sub-
Saharan Africa raises expectations that resource-constrained
HBV-endemic regions of the world may also improve access
to appropriate HBV treatment. Clearly, randomized trials
of HBV therapies in these affected regions, with longer
term follow-up to determine reductions in development of
cirrhosis or HCC, are needed.
ACKNOWLEDGEMENTS AND DISCLOSURES
We would like to thank the staff of the Gambia Liver Cancer
Study and The Gambia Hepatitis Intervention Study and the
staff and participants at the Bansang, Medical Research
Council and Royal Victoria hospitals for their contributions.
We thank Adam-Jeng Barry for excellent technical assis-
tance. We gratefully acknowledge the financial support of
the National Cancer Institute (Contract N02-CP40521) and
Medical Research Council (Fajara, The Gambia and United
Kingdom).
STATEMENT OF INTEREST
Drs Mendy, Hall, Whittle and Kirk contributed to study
design; Drs Kirk, Goedert, Hainaut, Rowland-Jones and
Whittle obtained funding support; Drs Lesi and Kirk con-
tributed to patient evaluation and clinical data collection;
Drs Mendy, Hainaut, McConkey and Kaye contributed to
 2009 Blackwell Publishing Ltd
HBV DNA and risk for HCC 121
laboratory analyses; Drs Mendy, Welzel, Kuniholm and
Kirk contributed to analysis of data; Drs Mendy, Welzel,
Kuniholm and Kirk contributed to manuscript preparation.
All authors contributed to critical review and editing of the
manuscript.
POTENTIAL COMPETING INTERESTS
None.
REFERENCES
1 Parkin DM, Bray FI, Devesa SS. Cancer burden in the year
2000. The global picture. Eur J Cancer 2001; 37(Suppl. 8):
S4–S66.
2 Kirk GD, Bah E, Montesano R. Molecular epidemiology of
human liver cancer: insights into etiology, pathogenesis and
prevention from The Gambia, West Africa. Carcinogenesis
2006; 27: 2070–2082.
3 Chu CJA, Lok S. Clinical significance of hepatitis B virus
genotypes. Hepatology 2002; 35: 1274–1276.
4 Kirk GD, Lesi OA, Mendy M et al. 249(ser) TP53 mutation
in plasma DNA, hepatitis B viral infection, and risk of
hepatocellular carcinoma. Oncogene 2005; 24: 5858–
5867.
5 Kirk GD, Turner PC, Gong Y et al. Hepatocellular carcinoma
and polymorphisms in carcinogen-metabolizing and DNA
repair enzymes in a population with aflatoxin exposure and
hepatitis B virus endemicity. Cancer Epidemiol Biomarkers
Prev 2005; 14: 373–379.
6 Yang HI, Lu SN, Liaw YF et al. Hepatitis B e antigen and the
risk of hepatocellular carcinoma. N Engl J Med 2002; 347:
168–174.
7 Yu MW, Yeh SH, Chen PJ et al. Hepatitis B virus geno-
type and DNA level and hepatocellular carcinoma: a
prospective study in men. J Natl Cancer Inst 2005; 97:
265–272.
8 Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carci-
noma across a biological gradient of serum hepatitis B virus
DNA level. JAMA 2006; 295: 65–73.
9 Chen G, Lin W, Shen F et al. Past HBV viral load as predictor
of mortality and morbidity from HCC and chronic liver
disease in a prospective study. Am J Gastroenterol 2006;
101: 1797–1803.
10 Iloeje UH, Yang HI, Su J et al. Predicting cirrhosis risk based
on the level of circulating hepatitis B viral load. Gastroen-
terology 2006; 130: 678–686.
11 Kirk GD, Lesi OA, Mendy M et al. The Gambia Liver Cancer
Study: infection with hepatitis B and C and the risk of
hepatocellular carcinoma in West Africa. Hepatology 2004;
39: 211–219.
12 Whittle HC, Bradley AK, McLauchlan K et al. Hepatitis B
virus infection in two Gambian villages. Lancet 1983; 1:
1203–1206.
13 Bah E, Parkin DM, Hall AJ et al. Cancer in the Gambia:
1988–97. Br J Cancer 2001; 84: 1207–1214.
14 Mendy ME, Fortuin M, Hall AJ et al. Hepatitis B virus DNA
in relation to duration of hepatitis B surface antigen car-
riage. Br J Biomed Sci 1999; 56: 34–38.
15 Mendy ME, Kaye S, van der Sande M et al. Application of
real-time PCR to quantify hepatitis B virus DNA in chronic
carriers in The Gambia. Virol J 2006; 3: 23.
16 Hung CH, Lu SN, Wang JH et al. Correlation between
ultrasonographic and pathologic diagnoses of hepatitis B
and C virus-related cirrhosis. J Gastroenterol 2003; 38:
153–157.
17 Lin DY, Sheen IS, Chiu CT et al. Ultrasonographic changes
of early liver cirrhosis in chronic hepatitis B: a longitudinal
study. J Clin Ultrasound 1993; 21: 303–308.
18 Kuniholm MH, Lesi OA, Mendy M et al. Aflatoxin exposure
and viral hepatitis in the etiology of liver cirrhosis in the
Gambia, West Africa. Environ Health Perspect 2008; 116:
1553–1557.
19 Wu CF, Yu MW, Lin CL et al. Long-term tracking of hepatitis
B viral load and the relationship with risk for hepatocellular
carcinoma in men. Carcinogenesis 2008; 29: 106–112.
20 Tang B, Kruger WD, Chen G et al. Hepatitis B viremia is
associated with increased risk of hepatocellular carcinoma
in chronic carriers. J Med Virol 2004; 72: 35–40.
21 Liu CJ, Chen BF, Chen PJ et al. Role of hepatitis B viral load
and basal core promoter mutation in hepatocellular carci-
noma in hepatitis B carriers. J Infect Dis 2006; 193: 1258–
1265.
22 Tsai FC, Liu CJ, Chen CL et al. Lower serum viral loads in
young patients with hepatitis-B-virus-related hepatocellular
carcinoma. J Viral Hepat 2007; 14: 153–160.
23 Milich DT, Liang J. Exploring the biological basis of hepatitis
B e antigen in hepatitis B virus infection. Hepatology 2003;
38: 1075–1086.
24 Chu CM, Hung SJ, Lin J et al. Natural history of hepatitis B e
antigen to antibody seroconversion in patients with normal
serum aminotransferase levels. Am J Med 2004; 116: 829–
834.
25 Chu CM, Liaw YF. Chronic hepatitis B virus infection
acquired in childhood: special emphasis on prognostic and
therapeutic implication of delayed HBeAg seroconversion.
J Viral Hepat 2007; 14: 147–152.
26 Liaw YF. Hepatitis B virus replication and liver disease
progression: the impact of antiviral therapy. Antivir Ther
2006; 11: 669–679.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article:
Table S1. HBV DNA detection and viral load among HCC
cases, Cirrhotics and controls stratified by HBeAg Status.
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials supplied
by the authors. Any queries (other than missing material)
should be directed to the corresponding author for the
article.
 2009 Blackwell Publishing Ltd
122 M. E. Mendy et al.
